CDK8/19 Inhibition Attenuates the Tolerance of Leukemia Cells to BCR-ABL1 Blockers in the Medium Conditioned by Bone Marrow Fibroblasts
Authors:
- 16 September 2026
- journal article
- research article
- Published by Pleiades Publishing Ltd in Cell and Tissue Biology
- Vol. 20 (6) , 633-648
Abstract
Tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 have transformed the treatment of chronic myelogenous leukemia (CML) and other malignancies, including FLT3-ITD-positive acute myelogenous leukemia (AML). However, soluble factors produced by the bone marrow microenvironment can attenuate the cytotoxic response to TKIs. CDK8 and CDK19 are mediator-associated kinases involved in stimulus-induced transcriptional programs, thereby representing plausible targets for limiting the adaptive drug tolerance. Here, we used HS-5 bone marrow fibroblast-conditioned medium as a model of soluble niche support and examined its effects in K562 CML and MV4.11 AML-cells treated with catalytic BCR-ABL inhibitors (imatinib, dasatinib, vamotinib, and olverembatinib) or with the allosteric blocker asciminib. In K562 cells, the conditioned medium reproducibly diminished TKI-induced accumulation of subG1 nuclei, indicating an attenuated DNA fragmentation. YO-PRO-1/propidium iodide staining further showed a redistribution from terminal cell damage by a short-term (72 h) treatment. Protective effects remained sustained for at least 9 days of intermittent exposure to TKI. Two structurally distinct, minimally cytotoxic CDK8/19 inhibitors senexin B (SenB) and SNX631, enhanced TKI-induced cell death in both regular and conditioned media. In MV4.11 cells, SenB and SNX631 increased the cytotoxicity of olverembatinib preferentially in the conditioned medium. Together, these data support a model in which soluble fibroblast-derived factor(s) delay the execution of TKI-induced cell death, while CDK8/19 inhibition antagonizes this adaptive response and restores TKI efficacy under bone marrow-mimicking conditions.Keywords
This publication has 46 references indexed in Scilit:
- Olverembatinib (HQP1351): a third-generation tyrosine kinase inhibitor in the treatment of hematologic and solid malignancies—a comprehensive review of clinical outcomesDiscover Oncology, 2026
- The role of the bone marrow microenvironment in leukemic stem cell resistance: Pathways of persistence and selectionCritical Reviews in Oncology/Hematology, 2025
- Treatment with asciminib after a prior tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemiaLeukemia Research, 2025
- Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemiaAnnals of Hematology, 2025
- Structures and compositional dynamics of Mediator in transcription regulationCurrent Opinion in Structural Biology, 2024
- The Mediator kinase module: an interface between cell signaling and transcriptionTrends in Biochemical Sciences, 2022
- Development of asciminib, a novel allosteric inhibitor of BCR-ABL1Critical Reviews in Oncology/Hematology, 2022
- Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemiaLeukemia Research, 2014
- Cytometry in cell necrobiology revisited. Recent advances and new vistasCytometry Part A, 2010
- Apoptosis Detection by Flow Cytometry2007